Welcome to our dedicated page for Accelerate Diagnostics news (Ticker: AXDX), a resource for investors and traders seeking the latest updates and insights on Accelerate Diagnostics stock.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) delivers innovative solutions for rapid infectious disease testing through its proprietary diagnostic platforms. This page provides investors and healthcare professionals with essential updates on company developments, financial performance, and technological advancements in antimicrobial susceptibility testing.
Access the latest press releases, earnings reports, and regulatory milestones related to AXDX's FDA-cleared systems. Our curated news collection helps stakeholders track progress in combating antibiotic resistance and improving sepsis management through accelerated diagnostics.
Key updates include product launch announcements, partnership developments, and clinical study results for platforms like the Accelerate Pheno® system. All content is verified through primary sources to ensure accuracy and relevance for investment research and clinical decision-making.
Bookmark this page for streamlined access to Accelerate Diagnostics' official communications. Check back regularly for real-time updates on innovations shaping the future of rapid in vitro diagnostics.
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) reported its third-quarter 2022 financial results with net sales of $3.0 million, a 3% decrease year-over-year. This decline was attributed to timing issues in capital equipment sales, although recurring revenues increased by 14%. The gross margin fell to 26%, down from 32%, due to rising manufacturing costs. The net loss widened to $15.7 million, or $0.18 per share. Year-to-date, net sales rose 16% to $9.8 million, but gross margins decreased to 27%. The company ended the quarter with $55.4 million in cash and equivalents, amid ongoing investments in its next-generation AST platform.
Holzer & Holzer, LLC is investigating Accelerate Diagnostics, Inc. (NASDAQ:AXDX) for potential violations of federal securities laws. This follows the Company's announcement on October 21, 2022, indicating that the FDA mandated 510(k) clearance for its Accelerate Arc Products, leading to the discontinuation of marketing and distribution in the US. As a result, the stock price of AXDX has significantly dropped. Investors are encouraged to contact the firm if they incurred losses.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) will host a conference call on November 14, 2022, at 4:30 p.m. ET to discuss its 2022 third quarter results. This call will provide insights into the company's performance and future outlook. Interested parties can access the audio webcast at ir.axdx.com or call +1.877.883.0383 with the Elite Entry Number: 5844198. A replay will be available for 30 days following the event.
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) has announced a public offering of 17,500,000 shares of its common stock at $2.00 per share, aiming for gross proceeds of $35 million. The underwriting team includes William Blair & Company, Oppenheimer & Co., and Craig-Hallum Capital. A 30-day option for underwriters to purchase an additional 2,625,000 shares is also granted. The net proceeds are intended for general corporate purposes and commercialization efforts. The offering is set to close around August 23, 2022, pending customary conditions.
Accelerate Diagnostics (Nasdaq: AXDX) announced a public offering of its common stock on August 17, 2022. The company intends to grant underwriters a 30-day option to purchase an additional 15% of the shares offered at the public price, net of underwriting fees. Proceeds will be utilized for general corporate purposes and to support commercialization. The offering, subject to market conditions, is managed by William Blair & Company, Oppenheimer & Co., and Craig-Hallum Capital Group.
Accelerate Diagnostics, Inc. (AXDX) reported second-quarter 2022 net sales of $3.9 million, a 39% increase from the previous year. The company added 8 contracted instruments, bringing the total to 316 revenue-generating instruments. However, gross margin declined to 28% from 38%, attributed to rising manufacturing costs. The net loss was $17.8 million or $0.23 per share. SG&A costs decreased to $11.5 million, while R&D expenses rose to $7.6 million. A significant partnership with Becton Dickinson was also announced for global commercialization.
BD (Becton, Dickinson and Company) and Accelerate Diagnostics, Inc. have formed a global commercial collaboration to provide rapid antimicrobial identification and susceptibility diagnostics. This partnership allows BD to market the Accelerate Pheno® system and Arc™ module, which offer quicker results compared to traditional testing methods. The collaboration aims to enhance patient care by optimizing antibiotic use, potentially reducing healthcare costs, and addressing antimicrobial resistance. This initiative is expected to increase market penetration for both companies, improving healthcare outcomes globally.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) will host a conference call on August 15, 2022, at 4:30 PM ET to discuss its 2022 second quarter results. This call aims to provide insights into the company's performance and future outlook concerning its innovative diagnostic solutions that address antimicrobial resistance and sepsis. The Accelerate Pheno® and Accelerate Arc™ systems promise significantly faster results than traditional methods, optimizing patient treatment.
Accelerate Diagnostics, Inc. has announced the CE marking and commercialization of its Accelerate Arc Module and BC kit in Europe, significantly enhancing rapid microbial identification for positive blood cultures. This innovative system reduces wait times by hours and automates sample preparation, leading to substantial cost savings for healthcare facilities. The system's simple, load-and-go workflow enables effective use by lab technicians, facilitating quicker results than traditional methods. Following successful evaluations and interest from partners, this system is positioned to improve healthcare efficiency and outcomes in diagnosing infections.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that CEO Jack Phillips will present at the 42nd Annual William Blair Growth Stock Conference on June 7, 2022, at 10:00 AM Central Time. The session will include a live audiocast, accessible via the company's investor relations website, with a replay available for 30 days post-event.
The company focuses on in vitro diagnostics, offering systems that expedite antibiotic therapy decisions for bacteremic patients, achieving results 1 to 2 days faster than conventional methods.
